704 related articles for article (PubMed ID: 33021091)
41. Biological rationale for the design of polymeric anti-cancer nanomedicines.
Zhou Y; Kopeček J
J Drug Target; 2013 Jan; 21(1):1-26. PubMed ID: 23009337
[TBL] [Abstract][Full Text] [Related]
42. Mathematical modeling of the heterogeneous distributions of nanomedicines in solid tumors.
He H; Liu C; Liu Y; Liu X; Wu Y; Fan J; Zhao L; Cao Y
Eur J Pharm Biopharm; 2019 Sep; 142():153-164. PubMed ID: 31226367
[TBL] [Abstract][Full Text] [Related]
43. Reduction-sensitive polymeric nanomedicines: An emerging multifunctional platform for targeted cancer therapy.
Sun H; Zhang Y; Zhong Z
Adv Drug Deliv Rev; 2018 Jul; 132():16-32. PubMed ID: 29775625
[TBL] [Abstract][Full Text] [Related]
44. P-glycoprotein-targeted photodynamic therapy boosts cancer nanomedicine by priming tumor microenvironment.
Mao C; Li F; Zhao Y; Debinski W; Ming X
Theranostics; 2018; 8(22):6274-6290. PubMed ID: 30613297
[TBL] [Abstract][Full Text] [Related]
45. Tumor-Targeted Nanomedicine for Immunotherapy.
Cabral H; Kinoh H; Kataoka K
Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
[TBL] [Abstract][Full Text] [Related]
46. Survey of Clinical Translation of Cancer Nanomedicines-Lessons Learned from Successes and Failures.
He H; Liu L; Morin EE; Liu M; Schwendeman A
Acc Chem Res; 2019 Sep; 52(9):2445-2461. PubMed ID: 31424909
[TBL] [Abstract][Full Text] [Related]
47. Modulating tumor mechanics with nanomedicine for cancer therapy.
Zhao Q; Chen J; Zhang Z; Xiao C; Zeng H; Xu C; Yang X; Li Z
Biomater Sci; 2023 Jun; 11(13):4471-4489. PubMed ID: 37221958
[TBL] [Abstract][Full Text] [Related]
48. Nanomedicines as emerging platform for simultaneous delivery of cancer therapeutics: new developments in overcoming drug resistance and optimizing anticancer efficacy.
Hussain Z; Arooj M; Malik A; Hussain F; Safdar H; Khan S; Sohail M; Pandey M; Choudhury H; Ei Thu H
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1015-1024. PubMed ID: 29873531
[TBL] [Abstract][Full Text] [Related]
49. Recent advances in physiologically based pharmacokinetic and pharmacodynamic models for anticancer nanomedicines.
Byun JH; Han DG; Cho HJ; Yoon IS; Jung IH
Arch Pharm Res; 2020 Jan; 43(1):80-99. PubMed ID: 31975317
[TBL] [Abstract][Full Text] [Related]
50. Liposomes of Quantum Dots Configured for Passive and Active Delivery to Tumor Tissue.
Aizik G; Waiskopf N; Agbaria M; Ben-David-Naim M; Levi-Kalisman Y; Shahar A; Banin U; Golomb G
Nano Lett; 2019 Sep; 19(9):5844-5852. PubMed ID: 31424944
[TBL] [Abstract][Full Text] [Related]
51. Nanomedicines for Reactive Oxygen Species Mediated Approach: An Emerging Paradigm for Cancer Treatment.
Kwon S; Ko H; You DG; Kataoka K; Park JH
Acc Chem Res; 2019 Jul; 52(7):1771-1782. PubMed ID: 31241894
[TBL] [Abstract][Full Text] [Related]
52. Renal clearable nanocarriers: Overcoming the physiological barriers for precise drug delivery and clearance.
Peng C; Huang Y; Zheng J
J Control Release; 2020 Jun; 322():64-80. PubMed ID: 32194171
[TBL] [Abstract][Full Text] [Related]
53. Paclitaxel-loaded micelles enhance transvascular permeability and retention of nanomedicines in tumors.
Danhier F; Danhier P; De Saedeleer CJ; Fruytier AC; Schleich N; des Rieux A; Sonveaux P; Gallez B; Préat V
Int J Pharm; 2015 Feb; 479(2):399-407. PubMed ID: 25578367
[TBL] [Abstract][Full Text] [Related]
54. Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines.
Durymanov MO; Rosenkranz AA; Sobolev AS
Theranostics; 2015; 5(9):1007-20. PubMed ID: 26155316
[TBL] [Abstract][Full Text] [Related]
55. Functionalization of curcumin nanomedicines: a recent promising adaptation to maximize pharmacokinetic profile, specific cell internalization and anticancer efficacy against breast cancer.
Zhang J; Sun J; Li C; Qiao H; Hussain Z
J Nanobiotechnology; 2023 Mar; 21(1):106. PubMed ID: 36964547
[TBL] [Abstract][Full Text] [Related]
56. Strategies to enhance drug delivery to solid tumors by harnessing the EPR effects and alternative targeting mechanisms.
Zi Y; Yang K; He J; Wu Z; Liu J; Zhang W
Adv Drug Deliv Rev; 2022 Sep; 188():114449. PubMed ID: 35835353
[TBL] [Abstract][Full Text] [Related]
57. Receptor-based targeting of engineered nanocarrier against solid tumors: Recent progress and challenges ahead.
Akhter MH; Beg S; Tarique M; Malik A; Afaq S; Choudhry H; Hosawi S
Biochim Biophys Acta Gen Subj; 2021 Feb; 1865(2):129777. PubMed ID: 33130062
[TBL] [Abstract][Full Text] [Related]
58. Enhanced permeability and retention effect-focused tumor-targeted nanomedicines: latest trends, obstacles and future perspective.
Shekhar S; Chauhan M; Sonali ; Yadav B; Dutt R; Hu L; Muthu MS; Singh RP
Nanomedicine (Lond); 2022 Aug; 17(18):1213-1216. PubMed ID: 36136592
[No Abstract] [Full Text] [Related]
59. Quantitative Evaluation of the Enhanced Permeability and Retention (EPR) Effect.
Russell LM; Dawidczyk CM; Searson PC
Methods Mol Biol; 2017; 1530():247-254. PubMed ID: 28150206
[TBL] [Abstract][Full Text] [Related]
60. Possibilities of poly(D,L-lactide-co-glycolide) in the formulation of nanomedicines against cancer.
Holgado MA; Alvarez-Fuentes J; Fernández-Arévalo M; Arias JL
Curr Drug Targets; 2011 Jul; 12(8):1096-111. PubMed ID: 21443478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
